Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 4/20 | 0.57 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.46 |
| ▸ | MAPK7 | Q13164 | 7/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.45 |
| ▸ | GAK | O14976 | 1/20 | 0.45 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.45 |
| ▸ | DCLK2 | Q8N568 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.45 |
| ▸ | IGF1R | P08069 | 2/20 | 0.45 |
| ▸ | INSR | P06213 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15795524 | 0.84 | PTK2 (0.50) | PTK2MAPK7LRRK2TNK2GAK | |
| SCHEMBL1045858 | 0.80 | ZAP70 (0.69) | ZAP70LRRK2 | |
| SCHEMBL1158204 | 0.79 | ZAP70 (0.64) | ZAP70 | |
| SCHEMBL1048733 | 0.79 | ZAP70 (0.47) | ZAP70PTK2MAPK7LRRK2TNK2 | |
| SCHEMBL1048135 | 0.78 | ZAP70 (0.89) | ZAP70 | |
| SCHEMBL11296289 | 0.77 | ALK (0.50) | PTK2MAPK7LRRK2TNK2GAK | |
| SCHEMBL1158303 | 0.77 | ZAP70 (0.66) | ZAP70 | |
| SCHEMBL1049791 | 0.77 | ZAP70 (0.65) | ZAP70 | |
| SCHEMBL1049310 | 0.77 | ZAP70 (0.81) | ZAP70 | |
| SCHEMBL1050414 | 0.76 | ZAP70 (0.67) | ZAP70BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | claimed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | claimed |
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| WO-2009097287-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | FYN, SYK, RET | ZAP70 4/4885PTK2 54/4885MAPK7 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.